News for Incyte Corporation (INCY)

SINGAPORE, June 13, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab (registered as Niktimvo® in the United States) and retifanlimab (registered as Zynyz® in the U.S. and European Union) added to the current partnered portfolio of Minjuvi® (tafasitamab) and Pemazyre® (pemigatinib).

Air India Boeing jet crashes shortly after takeoff. Nvidia and Samsung to take minority stakes in robotics startup Skild AI - report. Chime Financial prices IPO at $27, above expected price.

MacroGenics, Inc. (MGNX), Tuesday announced an agreement with Sagard Healthcare Partners regarding a capped royalty interest on future global net sales of ZYNYZ or retifanlimab-dlwr, which is used for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.

**media[650467]**

Summary Incyte Corp (INCY), a global biopharmaceutical company, announced the granting of restricted stock unit awards (RSUs) totaling 16,550 shares of the comp

Incyte (INCY) grants RSUs to 19 new employees under its Inducement Stock Incentive Plan. The total award comprises 16,550 shares of common stock, vested

SAN FRANCISCO and SUZHOU, China, June 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ('HUTCHMED') (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination of sintilimab and fruquintinib for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (TKI) has been accepted for review by the China National Medical Products Administration (NMPA).

**media[646188]**

Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology As

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline prospects. Read the full analysis here on Seeking Alpha.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody

Incyte and Novartis settle Jakafi royalty dispute with a $280M payment and future royalty rate cuts. Read more here.

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase

Exploring the robust pipeline and commercial strategies of Syndax Pharmaceuticals Inc (SNDX).Delving into the financial intricacies and growth trajectory of SN

Incyte (Nasdaq:INCY) announced today that it will present at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 1:40 pm (PDT). The pr

The following slide deck was published by Incyte Corporation in conjunction with their 2025 Q1 earnings call.

Discover key insights from Incyte's Q1 2025 earnings: robust revenue growth, Jakafi success, new product launches, and pipeline updates driving long-term...

Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ETCompany ParticipantsGreg Shertzer - Director of Investor...

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.